Overall survival and DFS of all treated patients. The median survival time for the 473 treated patients enrolled on CALGB study 9222 was 1.5 years (95% CI, 1.3-1.8 years). The median DFS for the 342 patients who achieved a CR was 1 year (95% CI, 0.9-1.3 years). OS indicates overall survival.